Li Y, Chen M, Zhou Y, Tang C, Zhang W, Zhong Y, et al. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. Theranostics. 2020;10:3579-3593 pubmed publisher

Yang X, Cai W, Sun X, Bi Y, Zeng C, Zhao X, et al. Defined host factors support HBV infection in non-hepatic 293T cells. J Cell Mol Med. 2020;24:2507-2518 pubmed publisher

Yalamanchili C, Chittiboyina A, Haider S, Vasquez Y, Khan S, do Carmo J, et al. In search for potential antidiabetic compounds from natural sources: docking, synthesis and biological screening of small molecules from Lycium spp. (Goji). Heliyon. 2020;6:e02782 pubmed publisher

Joo M, Koo J, Kim T, Kim Y, Kim S. LRH1-driven transcription factor circuitry for hepatocyte identity: Super-enhancer cistromic analysis. EBioMedicine. 2019;40:488-503 pubmed publisher

D Aniello E, Fellous T, Iannotti F, Gentile A, Allarà M, Balestrieri F, et al. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach. Biochim Biophys Acta Gen Subj. 2019;1863:586-597 pubmed publisher

Lee J, Lee J, Cho Y. Peroxisome Proliferator-Activated Receptor α Agonist and Its Target Nanog Cooperate to Induce Pluripotency. J Clin Med. 2018;7: pubmed publisher

Vitale R, D Aniello E, Gorbi S, Martella A, Silvestri C, Giuliani M, et al. Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. Mar Drugs. 2018;16: pubmed publisher

Donvito G, Piscitelli F, Muldoon P, Jackson A, Vitale R, D Aniello E, et al. N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology. 2019;148:320-331 pubmed publisher

Guida F, Luongo L, Boccella S, Giordano M, Romano R, Bellini G, et al. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017;7:375 pubmed publisher

Dickey A, Pineda V, Tsunemi T, Liu P, Miranda H, Gilmore Hall S, et al. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. Nat Med. 2016;22:37-45 pubmed publisher

Makia N, Goldstein J. CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver. Mol Pharmacol. 2016;89:154-64 pubmed publisher

Oruqaj G, Karnati S, Vijayan V, Kotarkonda L, Boateng E, Zhang W, et al. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling. Proc Natl Acad Sci U S A. 2015;112:E2048-57 pubmed publisher

Wu Y, Wu Q, Beland F, Ge P, Manjanatha M, Fang J. Differential effects of triclosan on the activation of mouse and human peroxisome proliferator-activated receptor alpha. Toxicol Lett. 2014;231:17-28 pubmed publisher

Schäffer U, Baumeister R, Schulze E. Targeted purification of SnAvi-tagged proteins. Methods Mol Biol. 2014;1177:163-74 pubmed publisher

Yang M, Vasquez Y, Ali Z, Khan I, Khan S. Constituents from Terminalia species increase PPAR? and PPAR? levels and stimulate glucose uptake without enhancing adipocyte differentiation. J Ethnopharmacol. 2013;149:490-8 pubmed publisher

Aseem O, Barth J, Klatt S, Smith B, Argraves W. Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics. 2013;14:405 pubmed publisher